Drugs / IRAMPANEL
IRAMPANEL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02223507 | Aug → Sep 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02222961 | Nov 1999 → Jun 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02222974 | Jan → Aug 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRAMPANEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL29741 ↗ |
| Known as | BIIR 561 | ChEMBL registry synonym — accepted as the source's own label CHEMBL29741 ↗ |
| Known as | BIIR 561 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02222961 ↗ |
| Modality | Small molecule | — CHEMBL29741 ↗ |
| Route | Intravenous | “Intravenous Administration” NCT02222961 ↗ |